RBC Life Sciences Announces MPM Medical Expansion into Latin America
Monday March 31, 8:00 am ET
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences, Inc. (OTCBB: RBCL) today announced that its wholly owned subsidiary, MPM Medical, Inc., has entered into a 15-year exclusive distributorship agreement with Glenmark, Farmaceutica LTDA, a pharmaceutical distributor located in Sao Do Campo – SP, Brazil. Through this distribution agreement Glenmark retains exclusive marketing and distribution rights in Brazil for two of MPM’s unique wound care products, which are used by oncology patients suffering from adverse reactions to certain oncology treatments.
“We are extremely pleased to announce this partnership with Glenmark Farmaceutica for distribution of our products in Latin America,” stated Paul R. Miller, President of MPM Medical. “This agreement represents our first significant expansion into the international market place. Even more so, we are delighted that we can now offer our exceptional healing products to more people who are in need of relief.”
Under this agreement, Glenmark will market RadiaPlex Gel, a hydrogel uniquely designed to protect a patient’s skin from radiation reactions and to assist in healing the skin if a radiation reaction does occur, as well as OraMagicRx Oral Wound Rinse, a product designed to relieve pain associated with mouth sores that often develop as a result of radiation and chemotherapy treatments.
RBC Life Sciences develops, manufactures and markets high quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company’s management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company’s filings with the Securities and Exchange Commission.
Contact:
Halliburton Investor Relations
Geralyn DeBusk, 972-458-8000
gdebusk@halliburtonir.com
or
Chase Zavoina, 972-458-8000
czavoina@halliburtonir.com
or
Jeff Elliott, 972-458-8000
jelliott@halliburtonir.com
--------------------------------------------------------------------------------
Source: RBC Life Sciences, Inc.
AI
